NDAORALTABLET
Approved
Mar 1977
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 36m ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
OPTIMINE (azatadine maleate) is an oral first-generation H1-receptor antagonist approved in 1977 for allergic conditions. It works by competitively blocking histamine at H1 receptors, reducing allergic symptoms. The product is now approaching loss of exclusivity with significant generic competition in the antihistamine market.
LOE Approaching
Product is in decline phase with limited commercial growth opportunity; teams are likely consolidating or transitioning to newer-generation antihistamines.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on OPTIMINE offers limited career growth due to approaching loss of exclusivity and market decline; roles are primarily defensive and focused on managed transition to generic competition. Career advancement is constrained; this assignment is best suited for early-career professionals gaining experience in mature product management or for those transitioning toward portfolio exit strategies.
Brand Manager (legacy product management)
Worked on OPTIMINE at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.